Homepage
Author:
Siren Biotechnology, Inc.
Posted Date:
May 7, 2026
Siren Biotechnology Publishes Foundational AAV Immuno-Gene Therapy Data and Announces Presentations at ASGCT 2026
Siren Biotechnology, Inc.
May 7, 2026
Siren Biotechnology Announces FDA Clearance of Investigator-Initiated IND to Advance Phase 1 Study in Recurrent High-Grade Glioma
Siren Biotechnology, Inc.
May 4, 2026
Siren Biotechnology Receives FDA Fast Track Designation for SRN-101 for the Treatment of Recurrent High-Grade Glioma
Siren Biotechnology, Inc.
February 24, 2026
Siren Biotechnology Announces FDA Clearance of First IND, Advancing Company to Clinical Stage
Siren Biotechnology, Inc.
January 28, 2026
